Pharmacodiagnosis Test Targeting Oncology and Neurodegeneration

a neurodegeneration and drug therapy technology, applied in the field of medicine and biology, can solve the problems of less effective treatment and less broad implementation, and achieve the effect of better evaluating the treatment efficiency

Inactive Publication Date: 2013-12-05
FAURE LAURENCE
View PDF2 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0047]The other aspect of the present invention is the use of the genes and the proteins mentioned above as markers for the invasiveness and the metastatic aggressiveness of cancer cells of the prostate,—colon, bladder, melanoma, ovary, endometrium and cervix, and cancers in neurobiology or in ORL etc. . . . In fact, sequential pharmacodiagnostic tests during treatment monitoring will permit to observe, by comparing at different time points, variations of the expression level or of their silencing and therefore to better evaluate the treatment efficiency, to readjust these treatments in the case of a suitable multitherapy in such a way that the physiological equilibrium of the different products of genes involved in metabolic complexes are maintained. The plasticity of these equilibriums justifies the use of diagnostic biochips and for the therapeutic monitoring with the most pertinent genes of metabolic complexes involved in the physiology of anarchic proliferation in the case of breast canc

Problems solved by technology

The consequence would be a less effective processing and of less

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmacodiagnosis Test Targeting Oncology and Neurodegeneration
  • Pharmacodiagnosis Test Targeting Oncology and Neurodegeneration
  • Pharmacodiagnosis Test Targeting Oncology and Neurodegeneration

Examples

Experimental program
Comparison scheme
Effect test

example 1

Extraction of Proteins of the Liv21 Complex.

The MCF-7 Cell Line

[0222]The MCF-7 line is a non clonal human line of breast denocarcinoma cells. During their differentiation induced by exogenous factors, these cells develop a hypertrophy, membrane protrusions and a tendency to dissociate from one another. They acquire a secretory phenotype which is characterized by the appearance of numerous granules and of secretory canaliculi.

[0223]In vivo, these cells are relatively non metastatic and this low invasiveness is thought to be due to a low constitutive activity of the protein kinases C (PKCs) and to a relatively low level of expression of protein kinase C alpha.

[0224]This line is used in many studies on proliferation, differentiation and apoptosis. These studies use appropriate drugs, such as TNF for the induction of apoptosis, or TPA (12-O-tetradecanoyl phorbol-13-10 sumoate) for the induction of differentiation and therefore for the study of departure from the cell cycle.

Extraction of...

example 2

Mass Spectrometry

[0226]A mass spectrometry (MALDI) was realized for the LIV21 protein and its complex. The LIV21 protein (polynucleotide Liv21F) was digested with trypsin. The peptides derived from the digestion are solubilized in a solvent: acetonitrile / water (1 / 1) containing 0.1% of TFA (trifluoroacetic acid). A saturated solution of the alpha-cyano-4-hydroxycinnamic matrix was prepared in the same solvent. The same volume of the two solutions was taken and mixed together and 1 μl was deposited onto the MALDI plate for analysis. The mass spectrometry showed that the LIV21 protein and its complex digested with trypsin reveals hundred peptides following the band of gel extracted between 49 and 54 kD (i.e. FIGS. 3-5). The LIV21 protein was characterized by a molecular weight of 50 kD revealed by Western blotting and by a two-dimensional SDS PAGE gel (FIG. 2). But we find a product of 100 kD at 130 kD which could be a Liv21 dimer. (I.e description FIGS. 4, 5 and 6)

[0227]When it change...

example 3

Analysis of Sequences in the Proteomic Databases

[0228]Several peptides in the patent in listing of the patent characterize it:

SEQ ID No 51Peptide LIV21b FVFALILALMLSMCGSEQ ID No 5Peptide LIV21b KFFVFALILALMLSMCGADSHAKR

[0229]For example, the inventor obtained a very significant score of 81, hoped: 0.0012 for the histatin 3-2 variant with 52% of overlapping of sequences between the tested sample and histatin, this sequence SEQ ID No5 is commune to Liv21 and HIS3-HUMAN (FIGS. 6 and 7). Using different database and a ppm which differed to 20 to 50 ppm, we obtain the same sequence for the commune part: SEQ ID No 51.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Login to view more

Abstract

The present invention relates to the field of medicine and biology. It concerns a new test for screening and therapeutic follow-up in oncology. More particularly, it relates to diagnostic and/or therapeutic tests in oncology and on neurodegenerative diseases. Molecular targeting by peptide vectors and antibodies or by small interfering RNAs (siRNAs) opens a new concept of interdependence for diagnostic and therapeutic tools.

Description

CROSS REFERENCE TO RELATED APPLICATION[0001]This application is a continuation in part application of U.S. patent application Ser. No. 12 / 282,117 filed on Sep. 8, 2008. This application is also a continuation in part application of International Patent Application Serial No. PCT / FR2011 / 000155 filed on Mar. 18, 2011.FIELD OF THE INVENTION[0002]The present invention relates to the field of medicine and biology. It concerns a new test for screening and therapeutic follow-up in oncology. More particularly, it relates to diagnostic and / or therapeutic tests in oncology and on neurodegenerative diseases. Molecular targeting by peptide vectors and antibodies or by small interfering RNAs (siRNAs) opens a new concept of interdependence for diagnostic and therapeutic tools.[0003]The inventor highlights the mechanisms of molecular interactions and the interest of biochips dedicated according to cancers with a multi-therapy added with therapeutic additives to slow down the formation of these les...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C12Q1/68C12N15/113C07K14/47
CPCC12Q1/6886C07K14/47C12Q1/6883C12N15/113A61K31/7088A61K31/7105C12N2310/14C12Q2600/158C12Q2600/178C12N15/11
Inventor FAURE, LAURENCE
Owner FAURE LAURENCE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap